Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Genmab Seeks Label Expansion for Epkinly Combo Use in Japan
November 7, 2025
- Alfresa, K Pharma Tie Up on iPS Cell-Derived Therapy KP8011
November 7, 2025
- Fujifilm to Launch ADC-Focused CDMO Services First in Japan
November 7, 2025
- Otsuka Launches Global PIII for Drug-Resistant Tuberculosis Therapy
November 7, 2025
- Novo Nordisk Taps Keisuke Kotani as New Japan Chief
November 7, 2025
- Leqembi Sales Soar 153% in H1 FY2025; Eisai Pins Hopes on Self-Injector, Blood Tests
November 6, 2025
- Fuji, J&J Reach Agreement on Simponi Biosimilar for 2026 Debut
November 5, 2025
- Takeda Mulls Boost in Imports amid Kenketu Glovenin-I Suspension
November 5, 2025
- Takeda Halts Shipments of Kenketu Glovenin-I to Review Narita Plant Process
November 5, 2025
- Maruho, Nielsen Ink Licensing Deal for Common Warts Therapy in Asia
November 5, 2025
- MHLW Veteran Katsufumi Jo Joins BCG as Senior Advisor
November 5, 2025
- Mundipharma’s Anerem 20 mg Now Available in Japan
November 5, 2025
- Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
November 4, 2025
- Sumitomo Ups FY2025 Forecast on North America-Driven Profit Growth
November 4, 2025
- Daiichi Sankyo’s Profit Down on HER3-DXd Delay, One-Off CMO Costs
November 4, 2025
- Toho Adopts Poison Pill in Response to 3D’s Rising Stake
November 4, 2025
- Meiji-Daito Consortium Discussing Integration of 56 Generic Products
November 4, 2025
- J&J Seeks Nod for Talvey-Tecvayli Bispecific Combo in Multiple Myeloma
November 4, 2025
- Alpha Fusion Launches PI of Lead Radiopharmaceutical in Thyroid Cancer
November 4, 2025
- Ayumi to Take Over Astellas, Ono Osteoporosis Drugs
November 4, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…